157 related articles for article (PubMed ID: 27382394)
21. Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer With Modern Systemic Therapy.
Xu FF; Cao L; Xu C; Cai G; Wang SB; Qi WX; Chen JY
Front Oncol; 2022; 12():789198. PubMed ID: 35280719
[TBL] [Abstract][Full Text] [Related]
22. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
Tseng YD; Uno H; Hughes ME; Niland JC; Wong YN; Theriault R; Blitzblau RC; Moy B; Breslin T; Edge SB; Hassett MJ; Punglia RS
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):622-30. PubMed ID: 26461004
[TBL] [Abstract][Full Text] [Related]
23. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
[TBL] [Abstract][Full Text] [Related]
24. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.
Fodor J; Polgár C; Major T; Németh G
Strahlenther Onkol; 2003 Mar; 179(3):197-202. PubMed ID: 12627264
[TBL] [Abstract][Full Text] [Related]
25. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.
Moo TA; McMillan R; Lee M; Stempel M; Patil S; Ho A; El-Tamer M
Ann Surg Oncol; 2013 Oct; 20(10):3169-74. PubMed ID: 23975289
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
27. Impact of postmastectomy radiation therapy in T1-2 breast cancer patients with 1-3 positive axillary lymph nodes.
Yin H; Qu Y; Wang X; Ma T; Zhang H; Zhang Y; Li Y; Zhang S; Ma H; Xing E; Liu X; Xu Q
Oncotarget; 2017 Jul; 8(30):49564-49573. PubMed ID: 28484094
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors affecting postmastectomy locoregional recurrence in patients with early breast cancer: are intrinsic subtypes effective?
Mersin H; Gülben K; Berberoğlu U; Yazi M; Acun G; Kinaş V; Erdoğan S
World J Surg; 2011 Oct; 35(10):2196-202. PubMed ID: 21853356
[TBL] [Abstract][Full Text] [Related]
29. The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy.
Wu SG; He ZY; Li FY; Wang JJ; Guo J; Lin Q; Guan XX
Chin J Cancer; 2010 Jul; 29(7):668-76. PubMed ID: 20591219
[TBL] [Abstract][Full Text] [Related]
30. Effect of tumor-infiltrating lymphocytes depending on the presence of postmastectomy radiotherapy on the prognosis in pT1-2N1M0 breast cancer.
Zhang L; Tang T; Liu L; Li C; Li Y; Geng C
Front Oncol; 2023; 13():1175965. PubMed ID: 37601690
[TBL] [Abstract][Full Text] [Related]
31. Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy.
Li C; Wang J; Mo M; Yuan J; Luo J; Jin K; Wang X; Yang Y; Ma J; Mei X; Yang Z; Yu X; Chen X; Guo X
Cancer Manag Res; 2021; 13():3889-3899. PubMed ID: 34017195
[TBL] [Abstract][Full Text] [Related]
32. Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Zhang Y; Zhang Y; Liu Z; Qin Z; Li Y; Zhao J; Ma X; Yang Q; Han N; Zeng X; Guo H; Zhang N
J Oncol; 2021; 2021():6632635. PubMed ID: 33564308
[TBL] [Abstract][Full Text] [Related]
33. Which patients might benefit from postmastectomy radiotherapy in breast cancer patients with t1-2 tumor and 1-3 axillary lymph nodes metastasis?
Kong M; Hong SE
Cancer Res Treat; 2013 Jun; 45(2):103-11. PubMed ID: 23864843
[TBL] [Abstract][Full Text] [Related]
34. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
35. Locoregional recurrence risk factors and the impact of postmastectomy radiotherapy on patients with tumors 5 cm or larger.
Nagao T; Kinoshita T; Tamura N; Hojo T; Morota M; Kagami Y
Breast Cancer; 2014 May; 21(3):292-301. PubMed ID: 22890603
[TBL] [Abstract][Full Text] [Related]
36. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
[TBL] [Abstract][Full Text] [Related]
37. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
[TBL] [Abstract][Full Text] [Related]
38. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
[TBL] [Abstract][Full Text] [Related]
39. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer.
Truong PT; Olivotto IA; Speers CH; Wai ES; Berthelet E; Kader HA
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):797-804. PubMed ID: 14967436
[TBL] [Abstract][Full Text] [Related]
40. Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22).
Park HJ; Shin KH; Kim JH; Ahn SD; Kim SS; Kim YB; Park W; Kim YJ; Shin HS; Kim JH; Lee SY; Kim K; Park KR; Jeong BK
Oncotarget; 2017 Aug; 8(35):59800-59809. PubMed ID: 28938683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
